Results 31 to 40 of about 16,087 (221)

The effect of mild and moderate hepatic impairment on the pharmacokinetics, safety and tolerability of balcinrenone

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Balcinrenone (previously AZD9977) is a novel selective non‐steroidal mineralocorticoid receptor antagonist (MRA) with a differential mechanism of action relative to approved MRAs. The aim of this trial was to assess the pharmacokinetics, safety and tolerability of balcinrenone in participants with mild and moderate hepatic impairment ...
Anna L. Eriksson, Deeyen Karsanji, Bonifride Tuyishimire, Joanna Parkinson, Maria Heijer, Tadeusz Pawlik, Judith Hartleib‐Geschwindner, Maria Leonsson‐Zachrisson, Hans Ericsson   +8 more
wiley   +1 more source

Dapagliflozin Does Not Protect against Adriamycin-Induced Kidney Injury in Mice

Kidney & Blood Pressure Research
Introduction: Sodium-glucose cotransporter 2 (SGLT2) inhibitors target SGLT2 in renal proximal tubules and promote glycosuria in type 2 diabetes mellitus in humans and animal models, resulting in reduced blood glucose levels.
Jin Joo Cha, Hye-jin Park, Ji Ae Yoo, Jungyeon Ghee, Dae Ryong Cha, Young Sun Kang   +5 more
doaj   +1 more source

Update on long-term efficacy and safety of dapagliflozin in patients with type 2 diabetes mellitus

Therapeutic Advances in Endocrinology and Metabolism, 2015
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a novel class of antihyperglycaemic agents with an insulin-independent mode of action. Dapagliflozin is a member of the SGLT2 inhibitors class that has received marketing authorization in Europe and ...
Aris Liakos, Thomas Karagiannis, Eleni Bekiari, Panagiota Boura, Apostolos Tsapas   +4 more
doaj   +1 more source

Proximal tubular epithelia-specific transcriptomics of diabetic mice treated with dapagliflozin

Heliyon, 2022
Based on recent clinical trials using sodium-glucose co-transporter 2 inhibitor (SGLT2i) demonstrating the significant improvement of outcomes of diabetic kidney disease (DKD), the paradigm shift from “glomerulocentric” to “tubule centric ...
Noriko Uehara-Watanabe, Natsuko Okuno-Ozeki, Itaru Nakamura, Tomohiro Nakata, Kunihiro Nakai, Aya Yagi-Tomita, Tomoharu Ida, Noriyuki Yamashita, Michitsugu Kamezaki, Yuhei Kirita, Satoaki Matoba, Keiichi Tamagaki, Tetsuro Kusaba   +12 more
doaj   +1 more source

Regulatory harmonization: Evolution, globalization and future directions

British Journal of Clinical Pharmacology, EarlyView.
Regulatory harmonization has become an increasingly important and accepted approach to streamline regulatory review processes and expedite access to safe, effective and high‐quality medicines globally. This review explores the evolution and current status of regulatory harmonization, convergence and reliance initiatives.
Orin Chisholm, Elaine Y. L. Blair, Christine Y. Lu   +2 more
wiley   +1 more source

Current practice and guideline adherence in renal dose adjustment for patients with chronic kidney disease: A systematic review and meta‐analysis

British Journal of Clinical Pharmacology, EarlyView.
Aims To quantify prescribing adherence to renal dosing recommendations in adults with chronic kidney disease (CKD; Stage 3 and above) and to evaluate the clinical consequences of non‐adherence. Methods This systematic review and meta‐analysis was conducted in accordance with PRISMA 2020 guidelines and registered in PROSPERO (CRD42025620883).
Hager ElGeed, Ahmed Tehemar, Mohamed Gasimelseed, Ahmed Gharaibeh, Muhammad Abdul Hadi, Kazeem Yusuff, Amani Zidan, Ahmed Awaisu   +7 more
wiley   +1 more source

Role of Dapagliflozin in Protection of Contrast Induced Nephropathy in Patients Eligible for Angiographic Procedures [PDF]

Zagazig University Medical Journal
Background: Dapagliflozin has proved great effects extend beyond glycemic control, including reduction in cardiovascular events, kidney disease progression, and mortality.
Asmaa kenawy, Rehab Yaseen, Walaa farid, Eslam El Habashy   +3 more
doaj   +1 more source

Effects of dapagliflozin on the serum levels of fibroblast growth factor 21 and myokines and muscle mass in Japanese patients with type 2 diabetes: A randomized, controlled trial

Journal of Diabetes Investigation, 2020
Aims/Introduction Our aims were to examine the add‐on effects of a sodium–glucose cotransporter 2 inhibitor, dapagliflozin, compared with existing antidiabetes treatments, on anthropometric/metabolic parameters, the levels of an endocrine regulator ...
Hajime Yamakage, Masashi Tanaka, Takayuki Inoue, Shinji Odori, Toru Kusakabe, Noriko Satoh‐Asahara   +5 more
doaj   +1 more source

Safety outcomes of antidiabetic medications: A comprehensive review of the EU summaries of product characteristics and international clinical practice guidelines

British Journal of Clinical Pharmacology, EarlyView.
Aims Information on the safety profile of antidiabetic medications is essential for informed treatment decisions in type 2 diabetes mellitus. Although this information is available in regulatory documents of individual drugs, a comprehensive overview across all approved antidiabetics is lacking.
David Liang, Daniala L. Weir, Safana Thevasahayam, Vera H. M. Deneer, Arno Siebes, Helga Gardarsdottir   +5 more
wiley   +1 more source

Dapagliflozin induces vasodilation in resistance-size mesenteric arteries by stimulating smooth muscle cell KV7 ion channels

Heliyon, 2022
Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor that, in addition to glucose reduction, lowers systemic blood pressure. Here, we investigated if dapagliflozin could directly relax small mesenteric arteries that control peripheral ...
Ahasanul Hasan, Sreelakshmi N. Menon, Farzana Zerin, Raquibul Hasan   +3 more
doaj   +1 more source